DUXAP9 and hepatocellular carcinoma: LINC01296 was found to be aberrantly expressed in several malignancies, including hepatocellular carcinoma, osteosarcoma and oral squamous cell carcinoma, and LINC01296 could also regulate tumorigenesis and progression of cancers [17].